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Background  and  Purpose:  We  investigated  the  relationship  between  the  β-fibrinogen  gene  (FGB)  -455  G/A 
polymorphism  and  plasma  fibrinogen  levels  in  Korean  ischemic  stroke  patients.  We  also  determined  whether  the 
f r e q u e n c y  o f  t h e  - 4 5 5  G / A  p o l y m o r p h i s m  d i f f e r e d  b e t w e e n  t w o  s u b types  of  noncardioembolic  stroke:  large-artery 
atherosclerosis  (LAA)  and  small-vessel  occlusion  (SVO).
Methods: A  t o t a l  o f  2 6 7  p a t i e n t s  w i t h  n o n c a r d i o e m b o l i c  s t r o k e  w e r e  e n r o lled.  Plasma  fibrinogen  and  other  risk 
factors  for  stroke  were  evaluated.  FGB  -455  G/A  genotypes  were  determined  by  polymerase  chain  reaction  with 
r e s t r i c t i v e  e n z y m e  H a e  I I I  a n d  a u t o m a t i c  D N A  s e q u e n c i n g .
Results: T h e  F G B  - 4 5 5  G / A  p o l y m o r p h i s m  w a s  s i g n i f i c a n t l y  a s s o c i a t e d  w i t h  an  elevated  plasma  fibrinogen  level 
(p<0.001).  The  frequency  of  the  A  allele  in  Korean  stroke  patients  was  16.7%.  However,  the  frequency  of  the  -455 
G / A  p o l y m o r p h i s m  d i d  n o t  d i f f e r  b e t w e e n  L A A  a n d  S V O .
Conclusions:  The  plasma  fibrinogen  level  might  be  affected  by  the  -455  G/A  polymorphism  in  noncardioembolic 
stroke  patients.  However,  the  LAA  and  SVO  subtypes  of  ischemic  s t r o k e  w e r e  n o t  a f f e c t e d  b y  t h e  - 4 5 5  G / A  
polymorphism.
J  Clin  Neurol  4(1):17-22,  2008
Key  Words: Fibrinogen,  Polymorphism,  Stroke
Received:  January  16,  2008  /  Accepted:  March  4,  2008  /  Address  for  correspondence:  Myeong-Kyu  Kim,  MD
Department  of  Neurology,  Chonnam  National  University  Medical  School,  8  Hak-dong,  Dong-gu,  Gwangju  501-757,  Korea
Tel:  +82-62-220-6161,  Fax:  +82-62-228-3461,  E-mail:  mkkim@chonnam.ac.kr
* This  paper  was  supported  by  grant  no.  CUHRICM-U-2004006  from  the  Chonnam  University  Hospital  Research  Institute  of  Clinical  Medicine.
INTRODUCTION
Prospective studies with large samples have suggested 
that the plasma fibrinogen level is an independent 
risk factor for coronary artery disease or stroke.
1–3  It 
is well known that elevated plasma fibrinogen levels 
can be affected by environmental and genetic factors. 
It has been reported that some of the 10 or more 
genetic polymorphisms of the fibrinogen gene that 
have been investigated to date may be involved in 
elevation of the plasma fibrinogen level.
4–9  Polymor-
phisms of the β-fibrinogen gene (FGB) including the 
β-455 G/A polymorphism 򰠏 which is especially involved 
in the rate-limiting steps of the formation of the β
-chain 򰠏 have been shown to be closely related to 
elevation of the plasma fibrinogen level. Several studies 
have suggested that the FGB -455 G/A polymorphism 
is associated with an elevated plasma fibrinogen 
concentration and ischemic stroke.
10–12
In terms of subtypes of ischemic stroke, it has been 
suggested that the FGB -455 polymorphism increases 
the incidence of multiple lacunar infarction.
11 The 
FGB -455 polymorphism may also be associated with 
large-artery atherosclerosis (LAA) rather than small- 
vessel occlusion (SVO),
12  and hence there is controversy Journal of Clinical Neurology: Vol. 4, No. 1, 2008
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regarding the relationship between the subtypes of 
cerebral infarction and the FGB -455 polymorphism.
This study was designed to determine the relation-
ship between the FGB -455 polymorphism and plasma 
fibrinogen levels in patients with noncardioembolic 
stroke (LAA and SVO), and to elucidate whether the 
frequency of the FGB -455 polymorphism differs with 
the subtype of ischemic stroke.
MATERIALS AND METHODS
1. Subjects
This study investigated acute-onset (< 7 days) cerebral 
infarction patients who visited our clinic and were 
diagnosed using brain magnetic resonance imaging. 
The patients were divided into subtypes according to 
Trial of Org 10172 in Acute Stroke Treatment (TOAST) 
classification.
13 Patients with cardiogenic embolism, 
at least two etiologies, or with unknown etiologies at 
the time of diagnosis were excluded. Patients with 
the following potential factors that could affect plasma 
fibrinogen levels were also excluded: (1) administration 
of antiplatelet agents prior to the onset of cerebral 
infarction, (2) apparent infections, and (3) cancers. 
Infection was regarded as present if there was a 
positive history and/or clinical signs of any current 
infection in combination with laboratory findings 
(e.g., elevated C-reactive protein, leukocytosis of 
>12,000 cells/μL, or pyuria in urinalysis). Of 344 
patients who were initially recruited, 77 patients were 
excluded due to previous antiplatelet-agent medication 
(n=35), apparent infection (n=33), and cancer (n=9).
Demographic characteristics, medical history, and 
risk factors for cerebral infarction such as hypertension, 
diabetes mellitus, hyperlipidemia, and smoking were 
investigated in all subjects. Patients were diagnosed 
as hypertensive if they were currently receiving 
antihypertensive medication or had a systolic blood 
pressure of greater than 140 mmHg or a diastolic 
blood pressure of greater than 90 mmHg on two 
separate examinations. Patients were diagnosed as 
diabetes mellitus if they were currently undergoing 
treatment with insulin or oral hypoglycemic agents, 
or if their fasting blood glucose level was higher 
than 140 mg/dL on two separate examinations. Patients 
were diagnosed as hyperlipidemia if they were currently 
receiving lipid-lowering agents, or if their total 
cholesterol level and LDL-cholesterol level exceeded 
the normal limits (240 and 130 mg/dL, respectively). 
The smoking habit was defined as either smoking 
(current smokers and ex-smokers) or nonsmoking.
Blood samples were collected prior to any patient 
management. The plasma fibrinogen level was measured 
using a coagulation analyzer (CA-7000, Sysmex, IL, 
USA). Routine hematology, blood coagulation, and 
serum lipid tests were also performed. The study was 
approved by the ethics committee of our hospital, 
and all patients or their caregivers signed a consent 
form for the genetic analysis.
2. Genetic analysis
Genomic DNA was extracted from peripheral blood 
lymphocytes using a standard protocol. The polymerase 
chain reaction (PCR) primers for DNA -fragments in 
the promoter region of the fibrinogen gene -455 G/A 
polymorphism were 5’-TGT TTA GAA TTT GTT 
GAA CAT TTT ACC-3’ (sense) and 5’-GAG GAG 
TGC CCT AAA CTT CCC-3’ (antisense). PCR amp-
lification was performed with a 50-μL reaction volume 
containing 1 μL of DNA template, 1 μL of each of 
the sense and antisense primers, 4 μL of deoxy-
nucleotide triphosphate, 5 μL of MgCl2, and 0.5 μL 
of AmpliTaq Gold
TM  polymerase (Perkin Elmer, CT, 
USA). The amplification conditions were as follows: 
an initial denaturing step at 96℃ for 7 min, followed 
by 35 amplification cycles of denaturation at 94℃ 
for 30 sec, annealing at 58℃ for 30 sec, and extension 
at 72℃ for 30 sec, and a final extension step of 72℃ 
for 10 min. PCR products were electrophoresed on a 
2% agarose gel, and the amplified genomic DNA 
fragments were extracted from the gel and purified 
using a QIAquick
® gel extraction kit (QIAGEN, Hilden, 
Germany) according to the manufacturer’s instructions. 
After 45 μL of amplified PCR products was mixed 
with 5 U of restrictive enzyme Hae III and buffer, Lee SH, et al. β-Fibrinogen Gene -455 G/A Polymorphism in Stroke Patients
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Table 1. Demographic features, risk factors, and fibrinogen levels in noncardioembolic stroke patients according to genotypes of 
the  β-fibrinogen gene (FGB) -455 G/A polymorphism
Genotype (-455 G/A)
p
G/G (n=188) G/A+A/A (n=79)
Age, mean±SD, years 64.39±11.6  65.09±10.6 0.646*
Males, n  (%) 108 (57.45) 48 (60.76) 0.616
†
Risk factors
Hypertension,  n (%) 120 (63.8) 58 (73.4) 0.129
†
Diabetes,  n (%) 49 (26.1) 26 (32.9) 0.256
†
Hyperlipidemia,  n (%) 35 (18.6) 21 (26.6) 0.145
†
Smoking,  n (%) 30 (15.9) 11 (13.9) 0.674
†
Fibrinogen (mg/dL), mean±SD 262.71±59.8 297.67±79.6 0.001*
*Student’s  t test, 
†chi-square test
they were allowed to react at 37℃ for 4 hours. The 
final product was electrophoresed on a 4% gel con-
taining EtBr, and its genotypes were analyzed using 
a UV transilluminator. Direct sequencing was performed 
using BigDye terminator kits (PE Biosystems, CA, 
USA) to determine individual genotypes.
3. Data analysis
The frequency of analyzed genotypes, including a 
minor A allele, were determined. The study subjects 
were divided into wild (G/G) and mutant (G/A or 
A/A) groups according to genotypes, and demographic 
characteristics such as age and gender, risk factors 
for cerebral infarction such as hypertension, diabetes 
mellitus, hyperlipidemia, and smoking, and fibrinogen 
level were compared between the two groups. Addi-
tionally, variations in the frequencies of A allele with 
subtypes of cerebral infarction were investigated. 
Fibrinogen levels were compared between the wild 
and mutant groups in patients with LAA and those 
with SVO.
Statistical analyses were performed using SPSS 
software, version 12.0 (SPSS, IL, USA). Student’s t 
test and the chi-square test were used to compare not 
only fibrinogen levels and risk factors for cerebral 
infarction with respect to fibrinogen polymorphisms, 
but also clinical features and fibrinogen levels with 
respect to pathogenic mechanisms of cerebral infarction 
between the two groups.
RESULTS
1. FGB -455 G/A polymorphism in all patients
The 267 patients with cerebral infarction were 
aged 64.6±11.4 (mean±SD) years, and comprised 156 
(58.4%) males and 111 (41.6%) females. The risk 
factors for cerebral infarction were hypertension (178 
patients, 66.7%), diabetes mellitus (75 patients, 28.1%), 
and hyperlipidemia (56 patients, 21.1%).
The FGB -455 G/A polymorphism was present in 
79 (29.6%) patients. Overall, the wild (G/G), G/A, 
and A/A types were present in 188 (70.4%), 69 
(25.8%), and 10 (3.7%) patients, respectively. The 
overall frequency of the minor A allele was 16.7%.
Demographic characteristics such as age and gender, 
and risk factors for cerebral infarction such as hyper-
tension, diabetes mellitus, and smoking did not differ 
significantly between the wild and mutant groups. 
However, plasma fibrinogen levels were significantly 
higher in the mutant group than in the wild group 
(p=0.001, Table 1).
2. Plasma fibrinogen and the -455G/A polymor-
phism in LAA and SVO
1) Frequency of the -455 G/A polymorphism in 
LAA and SVO
One hundred and fifty-two patients had LAA and Journal of Clinical Neurology: Vol. 4, No. 1, 2008
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Table 2. Distribution of genotypes of the FGB –455 G/A 
polymorphism according to stroke subtype
Stroke subtype
Genotype
G/G G/A+A/A
LAA (n=152), % 70.39 29.61
SVO (n=115), % 70.43 29.57
LAA; large-artery atherosclerosis, SVO; small-vessel occlusion.
Table 3. Distribution of genotypes of the FGB –455 G/A 
polymorphism according to race 
Race
Genotype 
Reference no.
G/G G/A +A/A
Caucasian* 64.9 35.1 11
Caucasian
† 66.0 33.9 22
Japanese* 73 27 23
Chinese* 65.3 34.7 24
Korean* 70.4 29.6 Present study
Data in columns 2 and 3 are percentages relative to all the 
cases studied.
*Patients with cerebral infarction, 
†patients with myocardial 
infarction
the others had SVO according to the TOAST classifi-
cation. The mutant group contained 45 (29.61%) of 
the 152 patients with LAA and 34 (29.57%) of the 
115 patients with SVO. The frequency of the FGB 
-455 G/A polymorphism did not differ between the 
wild and mutant groups (Table 2).
2) Plasma fibrinogen levels according to the -455 
G/A polymorphism in LAA and SVO
Patients with LAA and those with SVO were 
divided into wild and mutant groups according to the 
-455G/A polymorphism. Plasma fibrinogen levels were 
higher in patients with the A allele in each of the 
LAA and SVO groups (p=0.003 and 0.011, respectively). 
However, the other factors did not differ significantly 
between the wild and mutant groups.
DISCUSSION
An elevated plasma fibrinogen level is known to 
be an independent risk factor for cerebral infarction, 
ischemic heart disease, venous thrombosis, and peri-
pheral artery disease.
1,14–17 Fibrinogen is an important 
protein involved in blood coagulation, and is synthesized 
in the liver. On activation in vivo, it is converted into 
fibrin and forms thrombi with subsequent hemostasis.
17–19 
The fibrinogen polymer consists of single α-, β-, and 
γ-chains, the gene clusters for each of which are 
located within a 50 kb region on the long arm of 
chromosome 4 (q28).
20  Although mRNA for each of 
the three chains is independently synthesized in the 
fibrinogen genes, the regulation of transcription by 
the three genes is known to be closely related. 
Several studies have suggested that synthesis of β
-fibrinogen is a rate-limiting step in the assembly of 
experimentally induced mature fibrinogen, suggesting 
that it is the most important factor affecting plasma 
fibrinogen levels.
20,21
This study investigated the relationship between 
the FGB -455 G/A polymorphism and plasma fibrinogen 
levels in patients with two subtypes of ischemic stroke: 
LAA and SVO. Although elevated plasma fibrinogen 
can contribute to the development of cardioembolism,
22 
this condition was excluded in the present study 
because the focus was on clarifying the debate about 
differences in the genetic influence of the -455 G/A 
polymorphism between LAA and SVO.
11,12
The  G→A substitution in the promoter region of 
FGB was associated with an increase in plasma 
fibrinogen levels in 267 patients with cerebral in-
farction. In a meta-analysis, Iacoviello et al. found 
that the fibrinogen levels were higher in patients 
with the A allele in 19 of 23 articles, which corres-
ponds well with the results of this study.
21
We initially suspected that genotypes of the FGB 
-455 G/A polymorphism would differ with race. 
However, the genotypes of patients with ischemic 
stroke or myocardial infarction were quite similar 
across different races (Table 3),
11,23–25 which suggests 
that the genotype of the FGB -455 G/A polymorphism 
does not vary with race. However, since our results 
and those of the studies referenced in Table 3 applied 
to patients with ischemic stroke or myocardial infarction, 
these findings might not be representative of all 
Koreans and other races.
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-455G/A polymorphism did not differ significantly 
between patients with LAA and those with SVO. 
Previous studies have found that this polymorphism 
is a risk factor for multiple lacunar cerebral infarction, 
namely SVO, with others suggesting that it is also a 
risk factor for LAA.
11,12 With regards to SVO, the A 
allele elevates the fibrinogen concentration in the 
circulation, which might contribute to the progression 
of arteriosclerosis primarily in smaller cerebral arteries 
with a slower blood flow. This would predispose to 
the development of occlusions in small cerebral 
arteries and finally to multiple lacunar infarcts.
11 
However, in patients with LAA, elevated fibrinogen 
concentrations eventually promote atherosclerosis. It 
has also been reported that fibrinogen is involved in 
the formation of thrombi and the development of 
early atherosclerotic plaques, and is closely associated 
with the progression of atherosclerotic plaques.
12 
Possible mechanisms underlying these observations 
are the affinity of fibrin to lipoprotein a and the 
proliferation of vascular smooth-muscle cells by 
FDP, a fibrinogen metabolite.
26
To the best of our knowledge, this is the first 
comparison of the FGB -455 G/A polymorphism 
between patients with LAA and those with SVO. 
Whilst we cannot confirm the relationship between 
FGB -455 G/A polymorphism and subtypes of 
cerebral infarction (LAA and SVO) from the results 
of this study, the absence of a significant difference 
in the frequency of this polymorphism between LAA 
and SVO suggests that it has little effect on different 
subgroups of ischemic stroke. However, the patho-
genic mechanisms underlying LAA and SVO might 
be similar,
27,28 and the FGB polymorphism might 
commonly contribute to the polygenic potential for 
the development of both types of ischemic stroke. 
LAA can be distinguished from SVO according to 
the TOAST classification, which is based on clinical 
determinations of ischemic stroke including neuro-
imaging findings (e.g., size of infarction and degree 
of arterial stenosis). However, the possibility of 
subgroups from the TOAST classification overlapping 
might make it difficult to elucidate the exact underlying 
pathogenic mechanisms.
Our study was subject to some limitations. The 
relationship between the baseline fibrinogen level 
before stroke and the -455 G/A polymorphism could 
not be determined since only ischemic stroke patients 
were enrolled (i.e., no healthy control subjects were 
included). Also, acute stroke patients were recruited, 
and their fibrinogen levels could have been elevated 
as an acute-phase reaction. Further examinations of 
the plasma fibrinogen level in the chronic state 
would provide more information about the relation-
ship between fibrinogen and the -455 G/A polymorphism.
In summary, the level of plasma fibrinogen was 
higher in ischemic stroke patients with the FGB -455 
A allele. The genotypes of the FGB -455 G/A poly-
morphism in Korean stroke patients were similar to 
those of other races. Also, the frequency of the 
polymorphism did not differ between patients with 
LAA and those with SVO. Further studies on the 
FGB -455 G/A polymorphism with larger series of 
patients and including healthy control subjects are 
needed to elucidate the underlying mechanisms.
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